Our Company
We are an experienced team with internal drug discovery and development expertise focused on building a pipeline of best-in-class oral drugs for liver and gastrointestinal diseases.
Focused on developing innovative drugs that materially benefit patients with liver and gastrointestinal diseases
Non-alcoholic steatohepatitis (NASH) is one of the most common liver diseases
Irritable bowel syndrome with diarrhea affects ˜9 million people in the US
Inflammatory bowel disease is increasing in prevalence worldwide
Programs
Our lead program is a portfolio of optimized next generation FXR agonists for the treatment of non-alcoholic steatohepatitis (NASH), inflammatory bowel diseases and irritable bowel syndrome with diarrhea. Beyond our FXR program, we are focused on building a pipeline of other novel drug candidates.